Idiopathic pulmonary fibrosis (IPF) is a clinical syndrome and considered the most common and the most lethal form of pulmonary fibrosis corresponding to the histologic and imaging pattern of UIP. It is more common in middle age or elderly men and diagnosed by:
- histological or imaging pattern of usual interstitial pneumonia (UIP) and
- absence of alternative causes such as drug toxicity, environmental exposure (e.g. asbestos) or collagen vascular disease (e.g. scleroderma, rheumatoid arthritis)
It tends to be commoner in males with most cases presenting in those over 50 years of age.
Patients typically present with progressive dyspnoea on exertion and chronic dry cough, finger clubbing, chest pain, fatigue, malaise, and weight loss. Pulmonary function test results may be normal in mild disease or shows restriction pattern (i.e. reduced vital capacity and total lung capacity but near normal residual volume). DICO is commonly decreased even in mild cases.
A multidisciplinary approach in a tertiary setting is strongly advised. Contributions from pulmonologists, chest radiologists, and chest pathologists are crucial in reaching the correct diagnosis of IPF.
In 2000, the American Thoracic Society (ATS) and European Respiratory Society (ERS) jointly agreed major and minor criteria for the diagnosis of IPF in the absence of a surgical lung biopsy 5:
- exclusion of other known causes of interstitial lung disease (e.g. toxic effects of certain drugs, environmental exposures, connective tissue diseases)
- abnormal results of pulmonary function studies, including evidence of restriction (reduced vital capacity, often with an increased FEV1/FVC ratio) and impaired gas exchange (increased PaO2, decreased PaO2 with rest or exercise, or decreased DLCO)
- bibasilar reticular abnormalities with minimal ground-glass opacities at high-resolution CT: definite UIP pattern on HRCT chest
- transbronchial lung biopsy or bronchoalveolar lavage shows no features to support an alternative diagnosis
- age >50 years
- insidious onset of otherwise unexplained dyspnoea on exertion
- duration of illness >3 months
- bibasilar inspiratory crackles (dry or “Velcro” type)
In 2011, these criteria were revised in a collaborative statement by the ATS, ERS, Japanese Respiratory Society (JRS) and Latin American Thoracic Association (ALAT) 12. The major and minor criteria were eliminated and only the following diagnostic criteria remain:
a) Exclusion of other known causes of interstitial lung disease (e.g. domestic and occupational environmental exposures, connective tissue disease, and drug toxicity)
b) The presence of a UIP pattern on HRCT in patients not subjected to surgical lung biopsy (diagnostic categories of UIP pattern based on HRCT chest - Fleischner Society guideline 2018)
c) Specific combinations of HRCT and surgical lung biopsy pattern in patients subjected to surgical lung biopsy.
IPF, as the name states, is idiopathic, however there is an association with concurrent or previous history of smoking in 60% of patients and genetic factors. Up to 5–20% of patients with IPF have a family history of interstitial lung disease (ILD) or pulmonary fibrosis. More recently it has been shown that fibroblasts in this process demonstrate neoplastic or neoproliferative characteristics 11.
The rs35705950 single-nucleotide polymorphism (SNP)—a promoter site of an airway mucin gene (MUC5B)—is strongly associated with IPF and familial pulmonary fibrosis and not seen in other secondary causes of lung fibrosis. Positive rs35705950 SNP in IPF patients is associated with slightly better prognosis and outcome.
Histology shows a UIP pattern which is characterised by spatial and temporal heterogeneity. One of the hallmarks is the absence of inflammation. Spatial heterogeneity denotes biopsy sample showing patchy lung involvement with normal lung interspace between diseased lung. Temporal heterogeneity denotes different stages of disease seen on a single specimen, including normal lung, interstitial fibrosis and fibroblastic foci 4.
The CT imaging findings complement the histology. It is more correct to describe the characteristic imaging pattern as UIP rather than IPF, the latter term assigned for the idiopathic clinical syndrome of UIP.
A UIP-pattern of fibrosis is characterised by honeycombing cysts and reticular septal thickening with subpleural and posterior basal predominance. Traction bronchiectasis can also be observed, however, this is a general feature of fibrosis not specific to the UIP-pattern 4. In a subgroup of patients the imaging findings of UIP overlap with NSIP and biopsy may be necessary to obtain the correct diagnosis.
Treatment and prognosis
The clinical course is that of gradual deterioration and the condition carries a rather poor prognosis with median survival ranging from 2.5 to 3.5 years from the time of diagnosis (at the time of initial writing) 2. Some reports have suggested a slowing of progression with treatment by pirfenidone or nintedanib 7,8.
Consider pulmonary fibrosis due to a known cause, such as:
- 1. Wittram C, Mark EJ, Mcloud TC. CT-histologic correlation of the ATS/ERS 2002 classification of idiopathic interstitial pneumonias. Radiographics. 23 (5): 1057-71. doi:10.1148/rg.235035702 - Pubmed citation
- 2. Souza CA, Müller NL, Flint J et-al. Idiopathic pulmonary fibrosis: spectrum of high-resolution CT findings. AJR Am J Roentgenol. 2005;185 (6): 1531-9. doi:10.2214/AJR.04.1599 - Pubmed citation
- 3. Lynch DA, Godwin JD, Safrin S et-al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am. J. Respir. Crit. Care Med. 2005;172 (4): 488-93. doi:10.1164/rccm.200412-1756OC - Pubmed citation
- 4. Mueller-mang C, Grosse C, Schmid K et-al. What every radiologist should know about idiopathic interstitial pneumonias. Radiographics. 27 (3): 595-615. doi:10.1148/rg.273065130 - Pubmed citation
- 5. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 2002;165 (2): 277-304. Am. J. Respir. Crit. Care Med. (link) - Pubmed citation
- 6. du Bois RM, Wells AU. Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis. Eur Respir J Suppl. 2002;32: 43s-55s. Pubmed citation
- 7. Noble PW, Albera C, Bradford WZ et-al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377 (9779): 1760-9. doi:10.1016/S0140-6736(11)60405-4 - Pubmed citation
- 8. Taniguchi H, Ebina M, Kondoh Y et-al. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010;35 (4): 821-9. doi:10.1183/09031936.00005209 - Pubmed citation
- 9. Chung J, Lynch D. American Journal of Roentgenology. 2016;206 (3): . doi:10.2214/AJR.15.15627
- 10. Gruden J. American Journal of Roentgenology. 2016;206 (3): . doi:10.2214/AJR.15.15674
- 11. Vancheri C, Failla M, Crimi N et-al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur. Respir. J. 2010;35 (3): 496-504. doi:10.1183/09031936.00077309 - Pubmed citation
- Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. (2011) American journal of respiratory and critical care medicine. 183 (6): 788-824. doi:10.1164/rccm.2009-040GL - Pubmed